ERBB2 and neoplasm: In patient 2366, VAF for the SNP rs1309838194 in ERBB2 changed from around 50% (heterozygous at baseline time point) to 80% during follow-up, which indicated increased tumor-derived DNA in plasma and may be associated with disease progression.